SCOTUS rules in Life Tech v Promega: One is not enough

Managing IP is part of Legal Benchmarking Limited, 4 Bouverie Street, London, EC4Y 8AX

Copyright © Legal Benchmarking Limited and its affiliated companies 2024

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

SCOTUS rules in Life Tech v Promega: One is not enough

Life technologies 165

The Supreme Court has reversed the Federal Circuit in Life Tech v Promega, ruling that manufacture and exportation of a single component of a patented invention assembled in another country is not enough for infringement in the US. However, as a concurring opinion and observers note, the court did not indicate how much more than one is enough

Unlock this content.

The content you are trying to view is exclusive to our subscribers.

To unlock this content:

Take a Free Trial or Login
more from across site and ros bottom lb

More from across our site

The combined firm, which will operate under the Venner Shipley name and have 46 partners, will go live in December
Vidal, who recently announced her departure from the USPTO, said she decided to rejoin the firm because of its team and culture
Osborne Clarke said John Linneker’s experience, including acting for SkyKick in the seminal dispute with Sky, will be a huge asset to the firm
Fieldfisher led arguments in court before Kirkland & Ellis took over shortly after SkyKick was acquired, it was revealed last week
Lawyers at Finnegan and Fross Zelnick explain why privacy formed a natural extension of their firms’ IP practices and share expansion plans
The news that USPTO director Kathi Vidal is to step down early and WIPO’s aims for a design law treaty were among the biggest IP talking points this week
The firm, which celebrates its 10th anniversary this weekend, has appointed a new head of trademarks and is planning further expansion
Practitioners say they’re receiving more correspondence from opposing parties that could be AI-generated
Sapna Palla, who joins the firm from A&O Shearman, said she was impressed by its work with major life sciences businesses
The court’s decision will have brands and their advisers ‘desperately reviewing’ portfolios and filing strategies, sources predict
Gift this article